Clinical Trials

Text Size A A

E-Mail to a Friend



secret  Click to Play Audio


Send To Friend

Prostate Cancer

ARN-509 for Castration-Resistant Prostate Cancer
An Open-Label, Phase 1/2, Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Patients With Progressive Advanced Castration-Resistant Prostate Cancer
Status Conditions Phase Study ID
Recruiting Prostate Cancer Phase I/II NCT01171898
Summary

The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer. Patients will first be enrolled into Phase 1 of the study to identify a tolerable dose for the Phase 2 portion of the study. In the Phase 2, 3 different cohorts of patients will be enrolled to evaluate the safety and activity of ARN-509.


Investigator
Celestia S. Higano, MD
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)

NON-METASTATIC CRPC

Inclusion Criteria

  1. Histologically or cytologically proven prostate cancer with high risk for development of metastases, defined as either a PSA value >=8 ng/mL within the last 3 months or PSA Doubling Time <=10 months
  2. Ongoing androgen depletion therapy with a Gonadotropin Releasing Hormone (GnRH) analogue or inhibitor, or orchiectomy (i.e., surgical or medical castration)
  3. Castrate levels of serum testosterone of less than or equal to 50 ng/dL
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  5. A life expectancy of at least 3 months

Exclusion Criteria

  1. Distant metastases, including CNS and vertebral or meningeal involvement
  2. Prior treatment with MDV3100
  3. Prior treatment with abiraterone
  4. Prior treatment with ketoconazole
  5. Concurrent treatment with medications known to have seizure potential
  6. Concurrent treatment with corticosteroids. If they are already on steroids, patients will be allowed to enroll on the study but will need to taper off as soon as possible.
  7. QTc > 450 msec
  8. History of seizure or condition that may predispose to seizure
  9. Evidence of severe or uncontrolled systemic disease or HIV infection

METASTATIC CRPC, TREATMENT-NAIVE

Inclusion Criteria

  1. Histologically or cytologically proven prostate cancer with progressive disease based on either PSA or radiographic progression
  2. Ongoing androgen depletion therapy with a Gonadotropin Releasing Hormone (GnRH) analogue or inhibitor, or orchiectomy (i.e., surgical or medical castration)
  3. Castrate levels of serum testosterone of less than or equal to 50 ng/dL
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  5. A life expectancy of at least 3 months

Exclusion Criteria

  1. History of, or current metastases in the brain or untreated spinal cord compression
  2. Prior treatment with MDV3100
  3. Prior treatment with abiraterone
  4. Prior treatment with ketoconazole
  5. Concurrent treatment with medications known to have seizure potential
  6. Concurrent treatment with corticosteroids. If they are already on steroids, patients will be allowed to enroll on the study but will need to taper off as soon as possible.
  7. QTc > 450 msec
  8. History of seizure or condition that may predispose to seizure
  9. Evidence of severe or uncontrolled systemic disease or HIV infection

METASTATIC CRPC, CHEMOTHERAPY-NAIVE, POST-ABIRATERONE

Inclusion Criteria

  1. Histologically or cytologically proven prostate cancer with progressive disease based on either PSA or radiographic progression
  2. Ongoing androgen depletion therapy with a Gonadotropin Releasing Hormone (GnRH) analogue or inhibitor, or orchiectomy (i.e., surgical or medical castration)
  3. Castrate levels of serum testosterone of less than or equal to 50 ng/dL
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  5. A life expectancy of at least 3 months
  6. Patients must have received a minimum of 6 months of abiraterone treatment prior to disease progression

Exclusion Criteria

  1. History of, or current metastases in the brain or untreated spinal cord compression
  2. Prior treatment with MDV3100
  3. Prior treatment with ketoconazole
  4. Concurrent treatment with medications known to have seizure potential
  5. Concurrent treatment with corticosteroids. If they are already on steroids, patients will be allowed to enroll on the study but will need to taper off as soon as possible.
  6. QTc > 450 msec
  7. History of seizure or condition that may predispose to seizure
  8. Evidence of severe or uncontrolled systemic disease or HIV infection
Last Updated
April 06, 2012
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.